PCSK9 and atherosclerosis: Thus, the use of non-statin LLAs such as ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and bile acid sequestrants becomes necessary to further lower the LDL-C, especially among patients with a high risk of ASCVD [6].